The recent surge in COVID-19 cases caused by the new and more contagious omicron variant of the coronavirus has taught us at least one thing: There's still a dire need for effective vaccines against this potentially deadly disease. Here's why this matters for investors.
Several companies are still looking to enter the coronavirus vaccine market, even though Pfizer and Moderna currently dominate it. One biotech that is slowly advancing a coronavirus vaccine candidate is Vaxart (NASDAQ: VXRT).
The San Francisco, CA-based company has significantly lagged the market in the past year, but could its lofty ambitions help it reverse course?
Source Fool.com